Defining Local-Regional Control and Its Importance in Locally Advanced Non-small Cell Lung Carcinoma-Reference-Cited by-同舟云学术

Defining Local-Regional Control and Its Importance in Locally Advanced Non-small Cell Lung Carcinoma

Published:2012-04 Issue:4 Volume:7 Page:716-722
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Machtay Mitchell,Paulus Rebecca,Moughan Jennifer,Komaki Ritsuko,Bradley J effrey,Choy Hak,Albain Kathy,Movsas Benjamin,Sause William T.,Curran Walter J.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference18 articles.

1. Impact of tumor control on survival in carcinoma of the lung treated with irradiation;Perez;Int J Radiat Oncol Biol Phys,1986

2. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis;Marino;Cancer,1995

3. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group;Perez;Cancer,1987

4. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients;Le Chevalier;J Natl Cancer Inst,1991

5. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group Eastern Cooperative Oncology Group and Southwest Oncology Group;Sause;Chest,2000

Cited by 155 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of mediastinal tumor burden and lymphatic spread in locally advanced non-small-cell lung cancer: A secondary analysis of the multicenter randomized PET-Plan trial;Radiotherapy and Oncology;2024-11

2. Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy with Helical TomoTherapy Versus Conventional Radiation Therapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer Receiving Concurrent Chemotherapy: A Multicenter, Randomized Phase 3 Trial;International Journal of Radiation Oncology*Biology*Physics;2024-10

3. Impact of Radiation Therapy on Serum Humanin and MOTS-c Levels in Patients with Lung or Breast Cancer;Current Radiopharmaceuticals;2024-09

4. Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial;The Lancet Oncology;2024-09

5. Durvalumab impacts progression-free survival while high-dose radiation >66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR);Radiotherapy and Oncology;2024-07